E Signoriello1, S Bonavita2, A Di Pietro2, G Abbadessa2, F Rossi2, G Miele2, S Casertano2, G Lus2. 1. Multiple Sclerosis Centre, II Division of Neurology, Department of Clinical and Experimental Medicine, University of Campania Luigi Vanvitelli, Italy. Electronic address: Elisabetta.signoriello@unicampania.it. 2. Multiple Sclerosis Centre, II Division of Neurology, Department of Clinical and Experimental Medicine, University of Campania Luigi Vanvitelli, Italy.
Abstract
OBJECTIVES: Ocrelizumab (OCR) is a humanized monoclonal antibody targeting CD20 antigen exposed on B cells surface. Kinetic of B-cells repopulation after depletion therapy shows high intra and inter-individual variability. The aim of this study was to explore the influence of Body Mass Index (BMI) on kinetic of B-cell repopulation after treatment with OCR and on treatment response. METHODS: 108 Multiple Sclerosis (MS) patients were enrolled at the time of the first dose of OCR administration and prospectively evaluated. Clinical, instrumental activity and disability progression were analyzed. According to B cells count, patients were divided into two groups: with fast (FR) and with slow (SR) repopulation rate, respectively. RESULTS: Significant reduction of disease activity was observed in all patients and a stabilization of disease was obtained in progressive patients. Patients with FR had higher BMI compared to patients with a SR (p<0.001). Contrariwise no correlation between repopulation rate and treatment effectiveness was disclosed. CONCLUSIONS: In a real world setting we confirmed the effectiveness of OCR in relapsing remitting and progressive patients; patients with higher BMI had a FR. This suggests considering BMI for administration schedule although further investigations with longer follow up could improve treatment protocol and patient selection.
OBJECTIVES:Ocrelizumab (OCR) is a humanized monoclonal antibody targeting CD20 antigen exposed on B cells surface. Kinetic of B-cells repopulation after depletion therapy shows high intra and inter-individual variability. The aim of this study was to explore the influence of Body Mass Index (BMI) on kinetic of B-cell repopulation after treatment with OCR and on treatment response. METHODS: 108 Multiple Sclerosis (MS) patients were enrolled at the time of the first dose of OCR administration and prospectively evaluated. Clinical, instrumental activity and disability progression were analyzed. According to B cells count, patients were divided into two groups: with fast (FR) and with slow (SR) repopulation rate, respectively. RESULTS: Significant reduction of disease activity was observed in all patients and a stabilization of disease was obtained in progressive patients. Patients with FR had higher BMI compared to patients with a SR (p<0.001). Contrariwise no correlation between repopulation rate and treatment effectiveness was disclosed. CONCLUSIONS: In a real world setting we confirmed the effectiveness of OCR in relapsing remitting and progressive patients; patients with higher BMI had a FR. This suggests considering BMI for administration schedule although further investigations with longer follow up could improve treatment protocol and patient selection.
Authors: Tobias Moser; Ciara O'Sullivan; Ferdinand Otto; Wolfgang Hitzl; Georg Pilz; Kerstin Schwenker; Cornelia Mrazek; Elisabeth Haschke-Becher; Eugen Trinka; Peter Wipfler; Andrea Harrer Journal: Ther Adv Neurol Disord Date: 2022-04-22 Impact factor: 6.430
Authors: D Baker; C A K Roberts; G Pryce; A S Kang; M Marta; S Reyes; K Schmierer; G Giovannoni; S Amor Journal: Clin Exp Immunol Date: 2020-08-01 Impact factor: 4.330